Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen, Mehmet; Gunduz, Mehmet; ATEŞ, ÖZTÜRK; BABACAN, TANER; SEVER, ALİ; AKIN, SERKAN; Ozisik, Yavuz; Altundag, Kadri

Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R., AKIN S., ...Daha Fazla

JOURNAL OF BUON, cilt.21, sa.4, ss.799-808, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 4
Basım Tarihi: 2016
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.799-808
Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose: Optimal duration of adjuvant trastuzumab therapy in early-stage HER2-positive, lymph node-negative breast cancer is unknown. To establish this, we compared 1-year and 9-week trastuzumab regimens in HER2-positive, lymph node-negative early-stage breast cancer patients.